Skip to main content
Premium Trial:

Request an Annual Quote

Intercardia Offers $15 Million to Acquire Transcell Technologies

Premium

RESEARCH TRIANGLE PARK, NC--Drug development company Intercardia here is aggressively expanding, with the company's most recent move being to sign a letter of intent to acquire combinatorial chemistry company Transcell Technologies, Monmouth Junction, NJ. Signed in November, the deal calls for Intercardia to pay approximately $15 million in stock for Transcell, which has a $48 million deal with Merck to discover and evaluate two antibacterial compounds.

The agreement specifies that Transcell shareholders will receive three installments of Intercardia stock worth a total of approximately $4 million. In addition, Inter cardia will issue stock options worth $3 million-$4 million to Transcell employees and issue $4 million of its stock to parent company Interneuron for other Transcell technology. Earlier last year, Intercardia acquired an 80 percent ownership of Renaissance Cell Technologies, which is focused on harnessing the growth potential of stem cells.

Filed under

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.